Meyka Pro banner
Zhaoke Ophthalmology Limited

Zhaoke Ophthalmology Limited (6622.HK) Stock Competitors & Peer Comparison

See (6622.HK) competitors and their performances in Stock Market.

6622.HKHKSE
HealthcareBiotechnology
HK$2.62
HK$0.03(1.13%)
Hong Kong Market is Open · 15:51

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
6622.HKHK$2.62-1.13%1.4B-4.78-HK$0.55N/A
4332.HKHK$1,850.00+0.00%998.5B45.81HK$40.38N/A
6160.HKHK$192.30-0.36%265B88.84HK$2.21N/A
2269.HKHK$38.86+0.10%160.9B30.39HK$1.28N/A
1801.HKHK$92.10-0.05%160.6B169.64HK$0.54N/A
6990.HKHK$517.50+1.17%120.6B-256.32-HK$2.02N/A
9926.HKHK$103.70+9.62%91B-73.72-HK$1.34N/A
3347.HKHK$37.64+0.27%46.3B39.06HK$0.98+0.38%
1530.HKHK$17.70+4.61%43.2B4.50HK$3.84+1.45%
6821.HKHK$118.80-2.94%42.9B38.98HK$3.05+1.26%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

6622.HK vs 4332.HK Comparison July 2026

6622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 6622.HK stands at 1.4B. In comparison, 4332.HK has a market cap of 998.5B. Regarding current trading prices, 6622.HK is priced at HK$2.62, while 4332.HK trades at HK$1,850.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

6622.HK currently has a P/E ratio of -4.78, whereas 4332.HK's P/E ratio is 45.81. In terms of profitability, 6622.HK's ROE is -0.13%, compared to 4332.HK's ROE of N/A. Regarding short-term risk, 6622.HK is more volatile compared to 4332.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 6622.HK.Check 4332.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions